Press Releases

Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2 -mutated meningiomas in the second quarter 2022 Received Fast Track Designation for REC-4881, a

SALT LAKE CITY, May 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conference: Bank of America 2022 Healthcare Conference —  May

SALT LAKE CITY, April 11, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for

SALT LAKE CITY, March 31, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: Piper Sandler AI/Machine Learning Conference — 

The total capital represents the largest seed financing for life science startups in Utah's history SALT LAKE CITY, March 30, 2022 / PRNewswire / --  Altitude Lab  today announced its first cohort of startups raised $54M in seed funding while incubating at Altitude Lab.

Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity and philanthropy SALT LAKE CITY, March 24, 2022 /

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicines Expanded our collaboration with Bayer to include the use of Recursion's OS to

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE

SALT LAKE CITY, March 3, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion's leadership team has decided that conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest

SALT LAKE CITY, March 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: KeyBanc Capital Markets Emerging Technology